- $14.78m
- -$3.80m
- $0.65m
- 23
- 20
- 46
- 20
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.97 | ||
Price to Tang. Book | 2.1 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 24.25 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -57.23% | ||
Return on Equity | -93.57% | ||
Operating Margin | -2235.33% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 2.29 | 5.42 | 2.82 | n/a | 0.65 | n/a | 0.77 | -21.26% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is its nafamostat formulation for direct intravenous (IV) infusion being explored as an investigational product for the antiviral treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. Its pre-filled syringe product candidates include Fedsyra and Phenylephrine.
Directors
- Adrian Adams NEC (70)
- Vincent Angotti CEO (53)
- Pamela Palmer CFD (58)
- Raffi Asadorian CFO (51)
- Badri Dasu OTH (58)
- Jill Broadfoot DRC (59)
- Richard Afable IND (67)
- Marina Bozilenko IND (55)
- Mark Edwards IND (63)
- Stephen Hoffman IND (67)
- Howard Rosen IND (63)
- Mark Wan IND (55)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- July 13th, 2005
- Public Since
- February 11th, 2011
- No. of Shareholders
- 46
- No. of Employees
- 15
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 16,992,977
- Address
- 1850 Gateway Drive, Suite 175, SAN MATEO, 94404
- Web
- https://talphera.com/
- Phone
- +1 6502163500
- Auditors
- WithumSmith Brown PC
Upcoming Events for TLPH
AcelRx Pharmaceuticals Inc Annual Shareholders Meeting
Q3 2024 AcelRx Pharmaceuticals Inc Earnings Release
Similar to TLPH
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
Alimera Sciences
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
FAQ
As of Today at 17:39 UTC, shares in Talphera are trading at $0.93. This share price information is delayed by 15 minutes.
Shares in Talphera last closed at $0.93 and the price had moved by -19.2% over the past 365 days. In terms of relative price strength the Talphera share price has underperformed the S&P500 Index by -35.71% over the past year.
The overall consensus recommendation for Talphera is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Talphera does not currently pay a dividend.
Talphera does not currently pay a dividend.
Talphera does not currently pay a dividend.
To buy shares in Talphera you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.93, shares in Talphera had a market capitalisation of $15.79m.
Here are the trading details for Talphera:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: TLPH
Based on an overall assessment of its quality, value and momentum Talphera is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Talphera is $4.42. That is 375.68% above the last closing price of $0.93.
Analysts covering Talphera currently have a consensus Earnings Per Share (EPS) forecast of -$0.87 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Talphera. Over the past six months, its share price has outperformed the S&P500 Index by +3.31%.
As of the last closing price of $0.93, shares in Talphera were trading +4.03% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Talphera PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.93.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Talphera's management team is headed by:
- Adrian Adams - NEC
- Vincent Angotti - CEO
- Pamela Palmer - CFD
- Raffi Asadorian - CFO
- Badri Dasu - OTH
- Jill Broadfoot - DRC
- Richard Afable - IND
- Marina Bozilenko - IND
- Mark Edwards - IND
- Stephen Hoffman - IND
- Howard Rosen - IND
- Mark Wan - IND